Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: The methyl pyrazinylketone isonicotinoyl hydrazone series

Journal of Medicinal Chemistry

Volumn 51, Issue 2, 2008, Pages 331-344

  Kalinowski, Danuta S ^a   Sharpe, Philip C ^b   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BENZOIC ACID; FUNCTIONAL GROUP; HYDRAZONE DERIVATIVE; IRON CHELATING AGENT; IRON COMPLEX; METHYLPYRAZINYLKETONE ISONICOTINOYLHYDRAZONE DERIVATIVE; NITROGEN; PYRAZINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROCHEMISTRY; ELECTRON; ELECTRON WITHDRAWAL EFFECT; HUMAN; HUMAN CELL; HYDROXYLATION; IRON BINDING CAPACITY; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; IRON TRANSPORT; OXIDATION; OXIDATION REDUCTION REACTION; PARAMETER; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDRAZONES; HYDROXYLATION; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; IRON RADIOISOTOPES; ISONICOTINIC ACIDS; KETONES; LIGANDS; OXIDATION-REDUCTION; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38349152440     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7012562     Document Type: Article

References (62)

1. Bergeron, R. J.; Bharti, N.; Wiegand, J.; McManis, J. S.; Yao, H.; Prokai, L. Polyamine-vectored iron chelators: The role of charge. J. Med. Chem. 2005, 48, 4120-4137.
2. Bergeron, R. J.; Wiegand, J.; Bharti, N.; Singh, S.; Rocca, J. R. Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution. J. Med. Chem. 2007, 50, 3302-3313.
3. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Bharti, N. The design, synthesis, and evaluation of organ-specific iron chelators. J. Med. Chem. 2006, 49, 7032-7043.
4. Bernhardt, P. V. Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalton Trans. 2007, 3214-3220.
5. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583.
6. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Ward, R. J.; Crichton, R. R. Evaluation of new iron chelators and their therapeutic potential. Inorg. Chim. Acta 2002, 339, 470-480.
7. Hershko, C.; Abrahamov, A.; Konijn, A. M.; Breuer, W.; Cabantchick, I. Z.; Pootrakul, P.; Link, G. Objectives and methods of iron chelation therapy. Bioinorg. Chem. Appl. 2003, 1, 151-168.
8. Olivieri, N. F.; Brittenham, G. M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89, 739-761.
9. Wong, C.; Richardson, D. R. Beta-thalassaemia: Emergence of new and improved iron chelators for treatment. Int. J. Biochem. Cell Biol. 2003, 35, 1144-1149.
10. Kontoghiorghes, G. J.; Pattichis, K.; Neocleous, K.; Kolnagou, A. The design and development of deferiprone (L1) and other iron chelators for clinical use: Targeting methods and application prospects. Curr. Med. Chem. 2004, 11, 2161-2183.
11. Richardson, D. R. The controversial role of deferiprone in the treatment of thalassemia. J. Lab. Clin. Med. 2001, 137, 324-329.
12. Olivieri, N. F.; Brittenham, G. M.; McLaren, C. E.; Templeton, D. M.; Cameron, R. G.; McClelland, R. A.; Burt, A. D.; Fleming, K. A. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N. Engl. J. Med. 1998, 339, 417-423.
13. Maggio, A.; D'Amico, G.; Morabito, A.; Capra, M.; Ciaccio, C.; Cianciulli, P.; Di Gregorio, F.; Garozzo, G.; Malizia, R.; Magnano, C.; et al. Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol. Dis. 2002, 28, 196-208.
14. Wanless, I. R.; Sweeney, G.; Dhillon, A. P.; Guido, M.; Piga, A.; Galanello, R.; Gamberini, M. R.; Schwartz, E.; Cohen, A. R. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002, 100, 1566-1569.
15. Nick, H. Iron chelation, quo vadis? Curr. Opin. Chem Biol. 2007, in press.
16. Kontoghiorghes, G. J. Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin. Drug Saf. 2007, 6, 235-239.
17. Becker, E.; Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 1999, 134, 510-521.
18. Bernhardt, P. V.; Chin, P.; Sharpe, P. C.; Richardson, D. R. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Trans. 2007, 3232-3244.
19. Richardson, D. R.; Mouralian, C.; Ponka, P.; Becker, E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 2001, 1536, 133-140.
20. Wong, C. S.; Kwok, J. C.; Richardson, D. R. PCTH: A novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim. Biophys. Acta 2004, 1739, 70-80.
21. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86, 4295-4306.
22. Becker, E. M.; Lovejoy, D. B.; Greer, J. M.; Watts, R.; Richardson, D. R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 2003, 138, 819-830.
23. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J. Biol. Inorg. Chem. 2003, 8, 866-880.
24. Chaston, T. B.; Watts, R. N.; Yuan, J.; Richardson, D. R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylke-tone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 2004, 10, 7365-7374.
25. Richardson, D. R.; Becker, E.; Bernhardt, P. V. The biologically active iron chelators 2- pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1999, C55, 2102-2105.
26. Armstrong, C. M.; Bernhardt, P. V.; Chin, P.; Richardson, D. Structural variations and formation constants of first-row transition metal complexes of biologically active aroylhydrazones. Eur. J. Inorg. Chem. 2003, 1145-1156.
27. Bernhardt, P. V.; Wilson, G. J.; Sharpe, P. C.; Kalinowski, D. S.; Richardson, D. R. Tuning the anti-proliferative activity of biologically active iron chelators: Characterisation of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J. Biol. Inorg. Chem. 2008, 13, 107-119.
28. Bernhardt, P. V.; Chin, P.; Sharpe, P. C.; Wang, J.-Y. C.; Richardson, D. R. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J. Biol. Inorg. Chem. 2005, 10, 761-777.
29. Edward, J. T.; Chubb, F. L.; Sangster, J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients. Can. J. Physiol. Pharmacol. 1997, 75, 1362-1368.
30. Kalinowski, D. S.; Richardson, D. R. Future of toxicology-iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem. Res. Toxicol. 2007, 20, 715-720.
31. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49, 6510-6521.
32. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 2007, 50, 3716-3729.
33. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood 2004, 104, 1450-1458.
34. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent anti-tumor activity that overcome resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906.
35. Darnell, G.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 1999, 94, 781-792.
36. Richardson, D. R.; Ponka, P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. 1994, 124, 660-671.
37. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979, 97, 317-321.
38. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O.; Necas, E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta 1979, 586, 278-297.
39. Richardson, D. R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1991, 89, 3025-3038.
40. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer coalface: Desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006, 12, 6876-6883.
41. Lovejoy, D. B.; Richardson, D. R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002, 100, 666-676.
42. Feun, L.; Modiano, M.; Lee, K.; Mao, J.; Marini, A.; Savaraj, N.; Plezia, P.; Almassian, B.; Colacino, E.; Fischer, J.; et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother. Pharmacol. 2002, 50, 223-229.
43. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
44. Richardson, D. R.; Bernhardt, P. Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-proliferative activity. J. Biol. Inorg. Chem. 1999, 4, 266-273.
45. Bernhardt, P. V.; Mattsson, J.; Richardson, D. R. Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg. Chem. 2006, 45, 752-760.
46. Johnson, D. K.; Pippard, M. J.; Murphy, T. B.; Rose, N. J. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J. Pharmacol. Exp. Ther. 1982, 221, 399-403.
47. Richardson, D. R. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities. Antimicrob. Agents Chemother. 1997, 41, 2061-2063.
48. Chaston, T. B.; Richardson, D. R. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: Implications for toxicity in the treatment of iron overload disease. J. Biol. Inorg. Chem. 2003, 8, 427-438.
49. Bernhardt, P. V.; Chin, P.; Richardson, D. R. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): Serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J. Biol. Inorg. Chem. 2001, 6, 801-809.
50. Chaston, T. B.; Richardson, D. R. Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. Am. J. Hematol. 2003, 73, 200-210.
51. St Pierre, T. G.; Richardson, D. R.; Baker, E.; Webb, J. A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells. Biochim. Biophys. Acta 1992, 1135, 154-158.
52. Klausner, R. D.; Van Renswoude, J.; Ashwell, G.; Kempf, C.; Schechter, A. N.; Dean, A.; Bridges, K. R. Receptor-mediated endocytosis of transferrin in K562 cells. J. Biol. Chem. 1983, 258, 4715-4724.
53. Fleming, M. D.; Trenor, C. C., III; Su, M. A.; Foernzler, D.; Beier, D. R.; Dietrich, W. F.; Andrews, N. C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 1997, 16, 383-386.
54. Edward, J. T.; Gauthier, M.; Chubb, F. L.; Ponka, P. Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Eng. Data 1988, 33, 538-540.
55. Bacchi, A.; Carcelli, M.; Costa, M.; Pelagatti, P.; Pelizzi, C.; Pelizzi, G. Versatile ligand behaviour of phenyl 2-pyridyl ketone benzoylhydrazone in palladium (II) complexes. J. Chem. Soc., Dalton Trans. 1996, 22, 492-501.
56. Farrugia, L. J. WinGX suite for small-molecule single crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837-838.
57. Sheldrick, G. M. SHELX97: programs for crystal structure analysis, release 97-2; University of Gottingen: Germany, 1997.
58. Farrugia, L. J. ORTEP-3 for windows -a version of ORTEP-III with a graphical user interface (GUI). J. Appl. Crystallogr. 1997, 30, 565.
59. Richardson, D. R.; Baker, E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1990, 1053, 1-12.
60. Richardson, D. R.; Baker, E. Intermediate steps in cellular iron uptake from transferrin. Detection of a cytoplasmic pool of iron, free of transferrin. J. Biol. Chem. 1992, 267, 21384-21389.
61. Baker, E.; Richardson, D.; Gross, S.; Ponka, P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992, 15, 492-501.
62. Dean, R. T.; Nicholson, P. The action of nine chelators on iron-dependent radical damage. Free Radical Res. 1994, 20, 83-101.